Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease

Area of Science:

• Pediatric Cardiology
• Cardiovascular Research
• Thrombosis Management

Background:

• Kawasaki disease is a leading cause of acquired heart disease in children.
• Coronary artery aneurysms and thrombi pose a significant risk of myocardial infarction and sudden death.
• Limited therapeutic options exist for managing mural thrombi in pediatric coronary aneurysms.

Observation:

• A 7-month-old boy with Kawasaki disease presented with massive mural thrombi in coronary aneurysms.
• Magnetic resonance imaging visualized thrombi in both proximal and distal coronary arteries.
• The thrombi resolved following intravenous and intracoronary thrombolytic therapy.

Findings:

• Tissue-type plasminogen activator effectively treated mural thrombi in coronary aneurysms caused by Kawasaki disease.
• Complete resolution of thrombi was confirmed by follow-up magnetic resonance imaging.
• The therapeutic approach demonstrated safety and efficacy in this pediatric case.

Implications:

• Intravenous and intracoronary thrombolytic therapy with tissue-type plasminogen activator is a potential strategy for Kawasaki disease patients with coronary thrombi.
• This treatment may reduce the risk of acute myocardial infarction and sudden cardiac death in pediatric populations.
• Further research is warranted to establish the long-term efficacy and safety of thrombolytic therapy in Kawasaki disease.